IL17A and chronic myelogenous leukemia, BCR-ABL1 positive: Similar to the findings of Th22 cells, the frequencies of PB or BM Th17 (CD4+ IL-17+) cells (Figure 1) were profoundly decreased (Figures 2(d) and 2(e)) in ND CML patients (0.82 ± 0.80% or 0.99 ± 0.60%; *P = 0.029 or *P = 0.008) compared with healthy controls (3.52 ± 2.28% or 2.23 ± 0.66%).